Trials / Completed
CompletedNCT04932941
MP1032 Treatment in Patients With Moderate to Severe COVID-19
A Randomized, Double-blind, Placebo-controlled, Multicenter, Proof-of-concept, Phase IIA Study of MP1032 Plus Standard of Care vs Standard of Care in the Treatment of Hospitalized Participants With Moderate to Severe COVID-19
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 132 (actual)
- Sponsor
- MetrioPharm AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MP1032 | Hard gelatin capsules for oral administration. |
| DRUG | Placebo | Placebo capsules matched to MP1032 for oral administration. |
Timeline
- Start date
- 2021-10-19
- Primary completion
- 2022-07-28
- Completion
- 2022-09-05
- First posted
- 2021-06-21
- Last updated
- 2023-06-29
- Results posted
- 2023-06-29
Locations
31 sites across 7 countries: United States, Bulgaria, France, Hungary, Italy, Romania, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04932941. Inclusion in this directory is not an endorsement.